Search Site
Home >> Signaling Pathways >> Cell Cycle/Checkpoint >> Cyclin-Dependent Kinases

Cyclin-Dependent Kinases

Antibodies

  1. Cat.No. Product Name Information
  2. T1055 cdc2 Antibody Polyclonal cdc2 antibody, reacts with total cdc2 protein, cross reacts with CDK2 and CDK3
  3. T1056 CDK4 Antibody Monoclonal CDK4 antibody, reacts with total CDK4 protein
  4. T1191 Phospho-cdc2 (Tyr15) Antibody Polyclonal Phospho-cdc2 (Tyr15) antibody, reacts with cdc2, CDK2, and CDK5 phosphorylated at Tyr14
  5. T1192 Phospho-CDK9 (Thr186) Antibody Polyclonal Phospho-CDK9 (Thr186) antibody, reacts with CDK9 phosphorylated at Thr186

Biochemicals

  1. Cat.No. Product Name Information
  2. A8882 THZ1 Top Seller covalent inhibitor of CDK7
  3. A8326 AZD-5438 Top Seller Potent CDK1/2/9 inhibitor
  4. A8412 Dinaciclib (SCH727965) Top Seller CDK inhibitor
  5. A8641 LEE011 orally available and highly specific CDK4/6 inhibitor
  6. A1794 LY2835219 potent and selective CDK4/6 inhibitor
  7. A8316 PD 0332991 (Palbociclib) HCl Top Seller Highly selective CDK4/6 inhibitor
  8. B1233 CDK4 inhibitor CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50=5.265 uM) respectively.
  9. A8335 Palbociclib (PD0332991) Isethionate Top Seller Highly selective CDK4/6 inhibitor
  10. A8501 PHA-848125 potent, ATP-competitive CDK inhibitor
  11. A8385 BMS265246 potent and selective CDK1/2 inhibitor
  12. A8640 Flavopiridol hydrochloride Flavopiridol hydrochloride is a pan-cdk inhibitor.
  13. A8639 Deferasirox Deferasirox (marketed as Exjade) is a rationally-designed oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias.
  14. A8565 Purvalanol B Purvalanol B has been shown to be a cyclin-dependent kinase inhibitor.
  15. A5719 AT7519 multi-CDK inhibitor
  16. A5700 BS-181 HCl highly selective CDK7 inhibitor
  17. A3336 CVT-313 CVT-313 is a cell-permeable purine analog that acts as a potent, selective, reversible, and ATP-competitive inhibitor of Cdk2 (IC50 = 0.5 uM for Cdk2/A and Cdk2/E; 4.2 uM for Cdk1/B; 215 uM for Cdk4/D1).
  18. A3303 CGP60474 CGP60474 is a potent inhibitor of cyclin-dependent kinase (CDK).
  19. A3295 CDK9 inhibitor 2 CDK9 inhibitor 2
  20. A3294 CDK9 inhibitor CDK9 inhibitor is a novel, selective CDK9 inhibitor for the treatment of HIV infection.
  21. A3293 CDK inhibitor II CDK inhibitor II is a potent CDK inhibitor.
  22. A3266 BS-181 BS-181 is a selective cyclin-dependent kinase inhibitor with an IC50 of 21 nM for the inhibition of CDK-activating kinase.
  23. A3198 AT7519 trifluoroacetate AT7519 trifluoroacetate
  24. A3197 AT7519 Hydrochloride AT7519 Hydrochloride
  25. A3417 Flavopiridol Flavopiridol
  26. A3575 LY2835219 free base LY2835219 free base
  27. A5459 PHA-793887 novel and potent CDK2, CDK5 and CDK7 inhibitor
  28. A1723 Roscovitine (Seliciclib,CYC202) potent CDK inhibitor
  29. A1980 SNS-032 (BMS-387032) Top Seller Potent and selective CDK inhibitor
  30. A3806 SCH900776 S-isomer potent, selective and orally bioavailable inhibitor of checkpoint kinase Chk1
  31. A3794 SB1317 novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3
  32. A3676 NVP-LCQ195 NVP-LCQ195
  33. A1986 Nu 6027 selective CDK1/2 inhibitor
  34. B4754 LDC000067 LDC000067 is a highly selective CDK9 inhibitor with IC50 of 44 nM, 55/125/210/ >227/ >227-fold selectivity over CDK2/1/4/6/7.
  35. B3707 ML167 highly selective Clk4 inhibitor
  36. B1085 LEE011 succinate hydrate LEE011 succinate hydrate is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.
  37. B1084 LEE011 succinate LEE011 succinate is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.
  38. B1083 LEE011 hydrochloride LEE011 Hcl is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.
  39. B1234 WHI-P180 hydrochloride WHI-P180 hydrochloride is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.
  40. B3277 AMG 925 FLT3/CDK4 dual kinase inhibitor
  41. A8643 WHI-P180 WHI-P180 is a potent inhibitors [with IC50 = 4.0 microM for epidermal growth factor receptor (EGFR) kinase inhibition] of the EGFR tyrosine kinase as well as Janus Kinase 3.
  42. A8642 R547 potent ATP-competitive CDK1/2/4 inhibitor
  43. B4665 CDK7-IN-1
  44. B4736 THZ1 Hydrochloride THZ1 is a covalent inhibitor of CDK7 with IC50 value of 3.2nM [1].
  45. A4467 SU 9516 Potent, selective cdk2 inhibitor (IC50 values are 0.022, 0.04, 0.2, >10, >10, 18 and >100 μM for cdk2, cdk1, cdk4, PKC, p38, PDGFR and EGFR respectively). Inhibits pRb phosphorylation causing enhanced pRB/E2F complex formation and induces G1 and G2-M cell cycle arrest. Transcriptionally downregulates Mcl-1 and has antiproliferative, cytostatic and pro-apoptotic effects in vitro.